Unicycive Therapeutics has laid the groundwork for entering a market targeted by Sanofi and Takeda, posting pivotal bioequivalence data on a candidate designed to improve compliance with kidney disease treatment regimens.
LOS ALTOS, Calif., Feb. 2, 2022 /PRNewswire/ -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, today announced the acceptance of two abstracts supporting the potential efficacy and safety of Renazorb (lanthanum dioxycarbonate) to be presented as posters at the National Kidney Foundation (NKF) Spring Clinical Meeting taking place April 6-10, 2022 in Boston. Renazorb is a second-generation lanthanum-based phosphate binding agent utilizing proprietary nanoparticle technology being developed for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD).
Barr's Generic Lanthanum Carbonate Receives Approval in U.S.
Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan designation for pegylated interferon lambda 1a (Lambda) as a potential treatment for chronic hepatitis delta virus (HDV) infection.
NEW DELHI: NatcoBSE 5.24 % Pharma today said it has received approval from the US health regulator to market Lanthanum Carbonate chewable tablets used in treatment of patients with end stage renal disease.